Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: A phase III study

Emilio Bajetta; Giuseppe Procopio; Laura Catena; Antonia Martinetti; Sara De Dosso; Sergio Ricci; Alberto S. Lecchi; Paolo F. Boscani; Stefano Iacobelli; Giacomo Carteni; Filippo De Braud; Paola Loli; Andreas Tartaglia; Roberto Bajetta; Leonardo Ferrari

doi:10.1002/cncr.22272

Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: A phase III study

Emilio Bajetta, Giuseppe Procopio, Laura Catena, Antonia Martinetti, Sara De Dosso, Sergio Ricci, Alberto S. Lecchi, Paolo F. Boscani, Stefano Iacobelli, Giacomo Carteni, Filippo De Braud, Paola Loli, Andreas Tartaglia, Roberto Bajetta, Leonardo Ferrari

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND. The noninferiority of a 6-week dosing schedule of lanreotide Autogel (Lan ATG) at a dose of 120 mg compared with a 3-week dosing schedule of lanreotide microparticles (Lan MP) at a dose of 60 mg was investigated in patients with neuroendocrine tumors (NET). METHODS. Patients who had sporadic, well differentiated NET with a low grade of malignancy were recruited for this open-label, Phase III, multicenter trial. Patients were randomized to receive either 3 deep subcutaneous injections of Lan ATG (120 mg, every 6 weeks) or 6 intramuscular injections of Lan MP (60 mg, every 3 weeks). Tumor markers, tumor size, and symptoms were assessed between baseline and Week 18. Success was classified as a response that ranged from disappearance to an increase

Original language	English
Pages (from-to)	2474-2481
Number of pages	8
Journal	Cancer
Volume	107
Issue number	10
DOIs	https://doi.org/10.1002/cncr.22272
Publication status	Published - Nov 15 2006

Keywords

Lanreotide Autogel
Microparticles
Neuroeodocrine tumors
Somatostatin analogues

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1002/cncr.22272

Cite this

Bajetta, E., Procopio, G., Catena, L., Martinetti, A., De Dosso, S., Ricci, S., Lecchi, A. S., Boscani, P. F., Iacobelli, S., Carteni, G., De Braud, F., Loli, P., Tartaglia, A., Bajetta, R., & Ferrari, L. (2006). Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: A phase III study. Cancer, 107(10), 2474-2481. https://doi.org/10.1002/cncr.22272

Bajetta, E, Procopio, G, Catena, L, Martinetti, A, De Dosso, S, Ricci, S, Lecchi, AS, Boscani, PF, Iacobelli, S, Carteni, G, De Braud, F, Loli, P, Tartaglia, A, Bajetta, R & Ferrari, L 2006, 'Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: A phase III study', Cancer, vol. 107, no. 10, pp. 2474-2481. https://doi.org/10.1002/cncr.22272

@article{c2b986f6dcec46abbd39746998357698,

title = "Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: A phase III study",

abstract = "BACKGROUND. The noninferiority of a 6-week dosing schedule of lanreotide Autogel (Lan ATG) at a dose of 120 mg compared with a 3-week dosing schedule of lanreotide microparticles (Lan MP) at a dose of 60 mg was investigated in patients with neuroendocrine tumors (NET). METHODS. Patients who had sporadic, well differentiated NET with a low grade of malignancy were recruited for this open-label, Phase III, multicenter trial. Patients were randomized to receive either 3 deep subcutaneous injections of Lan ATG (120 mg, every 6 weeks) or 6 intramuscular injections of Lan MP (60 mg, every 3 weeks). Tumor markers, tumor size, and symptoms were assessed between baseline and Week 18. Success was classified as a response that ranged from disappearance to an increase ",

keywords = "Lanreotide Autogel, Microparticles, Neuroeodocrine tumors, Somatostatin analogues",

author = "Emilio Bajetta and Giuseppe Procopio and Laura Catena and Antonia Martinetti and {De Dosso}, Sara and Sergio Ricci and Lecchi, {Alberto S.} and Boscani, {Paolo F.} and Stefano Iacobelli and Giacomo Carteni and {De Braud}, Filippo and Paola Loli and Andreas Tartaglia and Roberto Bajetta and Leonardo Ferrari",

year = "2006",

month = nov,

day = "15",

doi = "10.1002/cncr.22272",

language = "English",

volume = "107",

pages = "2474--2481",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "10",

}

TY - JOUR

T1 - Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors

T2 - A phase III study

AU - Bajetta, Emilio

AU - Procopio, Giuseppe

AU - Catena, Laura

AU - Martinetti, Antonia

AU - De Dosso, Sara

AU - Ricci, Sergio

AU - Lecchi, Alberto S.

AU - Boscani, Paolo F.

AU - Iacobelli, Stefano

AU - Carteni, Giacomo

AU - De Braud, Filippo

AU - Loli, Paola

AU - Tartaglia, Andreas

AU - Bajetta, Roberto

AU - Ferrari, Leonardo

PY - 2006/11/15

Y1 - 2006/11/15

N2 - BACKGROUND. The noninferiority of a 6-week dosing schedule of lanreotide Autogel (Lan ATG) at a dose of 120 mg compared with a 3-week dosing schedule of lanreotide microparticles (Lan MP) at a dose of 60 mg was investigated in patients with neuroendocrine tumors (NET). METHODS. Patients who had sporadic, well differentiated NET with a low grade of malignancy were recruited for this open-label, Phase III, multicenter trial. Patients were randomized to receive either 3 deep subcutaneous injections of Lan ATG (120 mg, every 6 weeks) or 6 intramuscular injections of Lan MP (60 mg, every 3 weeks). Tumor markers, tumor size, and symptoms were assessed between baseline and Week 18. Success was classified as a response that ranged from disappearance to an increase

AB - BACKGROUND. The noninferiority of a 6-week dosing schedule of lanreotide Autogel (Lan ATG) at a dose of 120 mg compared with a 3-week dosing schedule of lanreotide microparticles (Lan MP) at a dose of 60 mg was investigated in patients with neuroendocrine tumors (NET). METHODS. Patients who had sporadic, well differentiated NET with a low grade of malignancy were recruited for this open-label, Phase III, multicenter trial. Patients were randomized to receive either 3 deep subcutaneous injections of Lan ATG (120 mg, every 6 weeks) or 6 intramuscular injections of Lan MP (60 mg, every 3 weeks). Tumor markers, tumor size, and symptoms were assessed between baseline and Week 18. Success was classified as a response that ranged from disappearance to an increase

KW - Lanreotide Autogel

KW - Microparticles

KW - Neuroeodocrine tumors

KW - Somatostatin analogues

UR - http://www.scopus.com/inward/record.url?scp=33750980417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750980417&partnerID=8YFLogxK

U2 - 10.1002/cncr.22272

DO - 10.1002/cncr.22272

M3 - Article

C2 - 17054107

AN - SCOPUS:33750980417

SN - 0008-543X

VL - 107

SP - 2474

EP - 2481

JO - Cancer

JF - Cancer

IS - 10

ER -

Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: A phase III study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this